Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucio Luzzatto

Showing results (31-40 of 140) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|January 10, 2019
Hydroxyurea - An Essential Medicine for Sickle Cell Disease in AfricaLucio Luzzatto, Julie Makani
The New England Journal of Medicine|July 13, 2022
Breakthrough Hemolysis in PNH with Proximal or Terminal Complement InhibitionRosario Notaro, Lucio Luzzatto
British Journal of Haematology|January 25, 2018
The "escape" model: a versatile mechanism for clonal expansionLucio Luzzatto, Rosario Notaro
Cell|April 6, 2022
Of mice and men: From hematopoiesis in mouse models to curative gene therapy for sickle cell diseaseJulie Makani, Lucio Luzzatto
Nature|June 18, 2002
Haemoglobin's chaperoneLucio Luzzatto, Rosario Notaro
Pathogens (Basel, Switzerland)|December 22, 2023
<i>Plasmodium vivax</i> Malaria and G6PD TestingBenedikt Ley, Lucio Luzzatto
Blood|March 18, 2006
The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH)David J Araten, Lucio Luzzatto
The New England Journal of Medicine|July 2, 2015
Causality and Chance in the Development of CancerLucio Luzzatto, Pier Paolo Pandolfi
The New England Journal of Medicine|October 15, 2015
Causality and Chance in the Development of CancerLucio Luzzatto, Pier Paolo Pandolfi
Blood|August 2, 2002
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cellsLucio Luzzatto, Junia V Melo
Pageof 14

Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|January 10, 2019
Hydroxyurea - An Essential Medicine for Sickle Cell Disease in AfricaLucio Luzzatto, Julie Makani
The New England Journal of Medicine|July 13, 2022
Breakthrough Hemolysis in PNH with Proximal or Terminal Complement InhibitionRosario Notaro, Lucio Luzzatto
British Journal of Haematology|January 25, 2018
The "escape" model: a versatile mechanism for clonal expansionLucio Luzzatto, Rosario Notaro
Cell|April 6, 2022
Of mice and men: From hematopoiesis in mouse models to curative gene therapy for sickle cell diseaseJulie Makani, Lucio Luzzatto
Nature|June 18, 2002
Haemoglobin's chaperoneLucio Luzzatto, Rosario Notaro
Pathogens (Basel, Switzerland)|December 22, 2023
<i>Plasmodium vivax</i> Malaria and G6PD TestingBenedikt Ley, Lucio Luzzatto
Blood|March 18, 2006
The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH)David J Araten, Lucio Luzzatto
The New England Journal of Medicine|July 2, 2015
Causality and Chance in the Development of CancerLucio Luzzatto, Pier Paolo Pandolfi
The New England Journal of Medicine|October 15, 2015
Causality and Chance in the Development of CancerLucio Luzzatto, Pier Paolo Pandolfi
Blood|August 2, 2002
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cellsLucio Luzzatto, Junia V Melo
Pageof 14